CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS

MICA is a stress-induced protein that, as a rule, is not expressed in healthy tissues, but appears in large amounts on the surface of cells undergoing malignant transformation. In humans, this protein can either initiate antitumor immune response, or facilitate tumor cells for their escape of destru...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. V. Klinkova, E. G. Kuzmina, E. V. Abakushina, L. M. Kanevskiy, G. S. Neprina, V. V. Pavlov, E. I. Kovalenko
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2016
Materias:	malignant lymphomas lymphoproliferative diseases mica protein smica cytotoxic lymphocytes nkg2d receptor Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c26e3107be044d358c7ebfd5cee08345
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c26e3107be044d358c7ebfd5cee08345
record_format	dspace
spelling	oai:doaj.org-article:c26e3107be044d358c7ebfd5cee083452021-11-18T08:03:45ZCIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS1563-06252313-741X10.15789/1563-0625-2016-2-151-162https://doaj.org/article/c26e3107be044d358c7ebfd5cee083452016-04-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/998https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XMICA is a stress-induced protein that, as a rule, is not expressed in healthy tissues, but appears in large amounts on the surface of cells undergoing malignant transformation. In humans, this protein can either initiate antitumor immune response, or facilitate tumor cells for their escape of destruction. After shedding from tumor cell surface, soluble MICA enters blood circulation and contributes to decreased activity of effector cells, due to inactivation of NKG2D receptor. The aim of our study was to determine differences in circulating sMICA concentrations in sera of patients with different types of malignant lymphomas, and to evaluate the impact of sMICA upon NKG2D-positive cytotoxic lymphocytes. In experimental models with C1R-MICA cells, the MICA shedding was shown to occur from the surface of cultured tumor cells into the extracellular space. A reduced NKG2D expression dependent on sMICA concentration in the culture medium was demonstrated by flow cytometry in peripheral mononuclear cells, thus suggesting a role of serum sMICA in suppression of antitumor immune response. The sMICA detection was performed in patients with various types of B- or T-cell non-Hodgkin’s lymphomas by means of enzyme-linked immunosorbent assay. The groups of patients with increased sMICA content were identified and compared with the control group. Minimal amounts of serum sMICA were registered in the control group, with the median of 20 pg/ml. In a combined group of patients with various B-cell lymphomas, an increase in circulating sMICA amounts was shown, at the levels of more than 6.5 times exceeding the control values. The highest values of sMICA were recorded among the patients with chronic lymphocytic leukemia, diffuse large cell lymphoma, and multiple myeloma. Maximal sMICA levels among the investigated groups of patients were observed in the group of patients with T-cell anaplastic lymphoma (median of 574 pg/ml). The study provides preliminary evidence for a suppressive effect of different (immuno)chemotherapy components, in particular, rituximab and radiation therapy, upon serum sMICA contents in the lymphoma patients. Thus, elevated serum sMICA levels in patients with hematological malignancies may be considered as an additional criterion for application of the antitumor therapy. sMICA monitoring at different stages of cytostatic treatment may be useful in order to evaluate its efficiency.A. V. KlinkovaE. G. KuzminaE. V. AbakushinaL. M. KanevskiyG. S. NeprinaV. V. PavlovE. I. KovalenkoSPb RAACIarticlemalignant lymphomaslymphoproliferative diseasesmica proteinsmicacytotoxic lymphocytesnkg2d receptorImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 18, Iss 2, Pp 151-162 (2016)
institution	DOAJ
collection	DOAJ
language	RU
topic	malignant lymphomas lymphoproliferative diseases mica protein smica cytotoxic lymphocytes nkg2d receptor Immunologic diseases. Allergy RC581-607
spellingShingle	malignant lymphomas lymphoproliferative diseases mica protein smica cytotoxic lymphocytes nkg2d receptor Immunologic diseases. Allergy RC581-607 A. V. Klinkova E. G. Kuzmina E. V. Abakushina L. M. Kanevskiy G. S. Neprina V. V. Pavlov E. I. Kovalenko CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS
description	MICA is a stress-induced protein that, as a rule, is not expressed in healthy tissues, but appears in large amounts on the surface of cells undergoing malignant transformation. In humans, this protein can either initiate antitumor immune response, or facilitate tumor cells for their escape of destruction. After shedding from tumor cell surface, soluble MICA enters blood circulation and contributes to decreased activity of effector cells, due to inactivation of NKG2D receptor. The aim of our study was to determine differences in circulating sMICA concentrations in sera of patients with different types of malignant lymphomas, and to evaluate the impact of sMICA upon NKG2D-positive cytotoxic lymphocytes. In experimental models with C1R-MICA cells, the MICA shedding was shown to occur from the surface of cultured tumor cells into the extracellular space. A reduced NKG2D expression dependent on sMICA concentration in the culture medium was demonstrated by flow cytometry in peripheral mononuclear cells, thus suggesting a role of serum sMICA in suppression of antitumor immune response. The sMICA detection was performed in patients with various types of B- or T-cell non-Hodgkin’s lymphomas by means of enzyme-linked immunosorbent assay. The groups of patients with increased sMICA content were identified and compared with the control group. Minimal amounts of serum sMICA were registered in the control group, with the median of 20 pg/ml. In a combined group of patients with various B-cell lymphomas, an increase in circulating sMICA amounts was shown, at the levels of more than 6.5 times exceeding the control values. The highest values of sMICA were recorded among the patients with chronic lymphocytic leukemia, diffuse large cell lymphoma, and multiple myeloma. Maximal sMICA levels among the investigated groups of patients were observed in the group of patients with T-cell anaplastic lymphoma (median of 574 pg/ml). The study provides preliminary evidence for a suppressive effect of different (immuno)chemotherapy components, in particular, rituximab and radiation therapy, upon serum sMICA contents in the lymphoma patients. Thus, elevated serum sMICA levels in patients with hematological malignancies may be considered as an additional criterion for application of the antitumor therapy. sMICA monitoring at different stages of cytostatic treatment may be useful in order to evaluate its efficiency.
format	article
author	A. V. Klinkova E. G. Kuzmina E. V. Abakushina L. M. Kanevskiy G. S. Neprina V. V. Pavlov E. I. Kovalenko
author_facet	A. V. Klinkova E. G. Kuzmina E. V. Abakushina L. M. Kanevskiy G. S. Neprina V. V. Pavlov E. I. Kovalenko
author_sort	A. V. Klinkova
title	CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS
title_short	CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS
title_full	CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS
title_fullStr	CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS
title_full_unstemmed	CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS
title_sort	circulating mica protein in patients with malignant lymphomas
publisher	SPb RAACI
publishDate	2016
url	https://doaj.org/article/c26e3107be044d358c7ebfd5cee08345
work_keys_str_mv	AT avklinkova circulatingmicaproteininpatientswithmalignantlymphomas AT egkuzmina circulatingmicaproteininpatientswithmalignantlymphomas AT evabakushina circulatingmicaproteininpatientswithmalignantlymphomas AT lmkanevskiy circulatingmicaproteininpatientswithmalignantlymphomas AT gsneprina circulatingmicaproteininpatientswithmalignantlymphomas AT vvpavlov circulatingmicaproteininpatientswithmalignantlymphomas AT eikovalenko circulatingmicaproteininpatientswithmalignantlymphomas
_version_	1718422445085425664

CIRCULATING MICA PROTEIN IN PATIENTS WITH MALIGNANT LYMPHOMAS

Ejemplares similares